Update on the emerging role of telavancin in hospital-acquired infections

Obinna N Nnedu1
George A Pankey2

1Infectious Disease Department, Ochsner Clinic Foundation, New Orleans, LA, USA; 2Infectious Disease Research, Ochsner Clinic Foundation, New Orleans, LA, USA

Abstract: Telavancin is a lipoglycopeptide that has activity against Gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus and non-Van-A strains of vancomycin-resistant enterococci. It has been approved by the US Food and Drug Administration (FDA) for complicated skin and skin structure infections and hospital-acquired pneumonia. There is a need for more clinical studies to determine the role of telavancin in treating bacteremia and prosthetic device infections. In this review, we discuss the published data on the use of telavancin in treating hospital-acquired infections and provide an update on new research.

Keywords: telavancin, vancomycin, linezolid, Staphylococcus aureus

Introduction
Hospital-acquired infections cause high rates of morbidity and mortality. In addition to the human cost, the financial cost on hospitals is immense. The Centers for Disease Control and Prevention classifies hospital-acquired infections into four groups; hospital-associated pneumonia (HAP), surgical site infections (SSIs), central line-associated bloodstream infections (CLABSIs), and catheter-associated urinary tract infections (CAUTIs). Many hospital-acquired infections are caused by Gram-positive bacteria. Bacteria isolated from these infections are frequently resistant to routinely used antibiotics. Effective antimicrobial treatment of incident cases is an important cornerstone for decreasing the burden of hospital-acquired infections. Telavancin is a new lipoglycopeptide that has been approved by the US Food and Drug Administration (FDA) for treating complicated skin and skin structure infections (cSSSIs) and HAP. It has a broad range of activity against aerobic and anaerobic Gram-positive bacteria. In this review, we explore the possible role of telavancin in treating HAP, SSI, CLABSI, and CAUTI.

Microbiology and pharmacology
Telavancin has antimicrobial activity against drug-resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), and linezolid-resistant S. aureus.5–4 In vitro data also suggest a potential role in treating non-Van-A strains of vancomycin-resistant Enterococcus.4,5 The Van-A gene confers resistance by altering the binding site for glycopeptides from D-Ala–D-Ala to D-Ala–D-Lac. This mutation also decreases telavancin efficacy. In vitro synergy studies have shown synergy for combination of telavancin and rifampin in treating Enterococcus faecium resistant to both linezolid and vancomycin.6 Care must be taken, however, in interpreting in vitro synergy studies as they may not correlate with clinical efficacy.
A postmarketing study of 15,480 Gram-positive bacterial isolates from 89 countries obtained in 2010 showed that telavancin still maintained potent activity against these bacterial isolates. In the study, telavancin had low minimum inhibitory concentration (MIC) for methicillin-sensitive \textit{S. aureus} (MSSA) \((0.03–0.5)\), MRSA \((<0.015–0.5)\), and coagulase-negative staphylococci \((<0.015–1)\).

The FDA approved a revised broth microdilution method for telavancin in 2014. This new method is used for other lipoglycopeptides and provides more accurate MICs for Gram-positive organisms utilizing this method have been found to be lower, suggesting greater efficacy than previously thought. Utilizing this new broth microdilution method and new FDA breakpoints, a study of 10,920 nonduplicate isolates collected between 2011 and 2012 confirmed high-level activity against \textit{Staphylococcus}, \textit{Streptococcus}, and vancomycin-susceptible \textit{Enterococcus}. The study also confirmed that telavancin has decreased activity against Van-A strains of vancomycin-resistant enterococci.

Telavancin has also shown activity against a number of anaerobes, including \textit{Actinomyces}, \textit{Clostridium} species including \textit{C. difficile}, \textit{Eubacterium}, \textit{Lactobacillus}, \textit{Propionibacterium}, \textit{Peptostreptococcus}, and \textit{Corynebacterium}. However, there is a paucity of clinical studies looking at the role of telavancin to treat infections caused by anaerobic bacteria.

Telavancin has a hydrophobic side chain on the vancomycin sugar and a hydrophilic group in the 4’ position of amino acid 7. These properties allow telavancin to have a twofold mechanism of action. Firstly, it binds to the D-Ala D-Ala moiety on peptidoglycan precursors, disrupting the late stages of cell wall synthesis. Secondly, telavancin disrupts cell membrane potential leading to leakage of cytoplasmic material, and cell death. The dual mechanism of action allows for telavancin to have fourfold enhanced bactericidal activity as compared to vancomycin when treating MRSA infection in experimental mouse models.

Telavancin exhibits concentration-dependent bactericidal activity. The half-life of telavancin is 7–9 hours with a postantibiotic effect of 4–6 hours. These properties allow telavancin to be conveniently dosed once a day. The most important pharmacokinetic marker influencing efficacy is the ratio between area under the serum-concentration-vs-time curve vs MIC or area under the curve (AUC)/MIC ratio. Telavancin has been shown to be efficacious with AUC/MIC ratios >219. Pharmacokinetic studies have shown that doses of 10 mg/kg in individuals with normal kidney function achieve adequate AUC/MIC ratios. About 90% of administered telavancin is bound by albumin. It is primarily excreted unchanged by the kidney. Hence for those with impairment in their kidney function, the dose has to be adjusted.

Efficacy

**Hospital-associated pneumonia**

HAP is defined as a pneumonia that starts 48 hours or more after hospitalization. HAP may be divided into ventilator and nonventilator lung infections. The Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia (ATTAIN) studies I and II were Phase III trials that looked at the efficacy of telavancin for treating HAP. Both trials were designed as noninferiority trials comparing telavancin to vancomycin. Data pooled from both studies \((n=654)\) show similar cure rates between telavancin \((82\%)\) and vancomycin \((81\%)\) among clinically evaluable patients.

When study patients were restricted to those with \textit{S. aureus} as the sole pathogen \((n=298)\), cure rates were 86% for the telavancin arm and 75% for the vancomycin arm. In a subanalysis of only nonventilator-associated HAP \((n=519)\), cure rates were similar in the telavancin arm and in the vancomycin arm \((83\% vs 84\%)\). When the analysis was further restricted to those with MRSA-positive initial cultures \((n=223)\), there was again no statistically significant difference between cure rates in the telavancin arm \((74.8\%)\) vs the vancomycin arm \((79.3\%)\). Based on these data, the FDA has approved telavancin for use in treating HAP.

Another subgroup analysis was performed within the ATTAIN trials to compare efficacy of telavancin vs vancomycin for treating HAP associated with bacteremia. Bacteremic HAP was defined as patients with blood cultures positive for the same causative pathogen as the HAP. Fifty-nine participants had Gram-positive bacteremia with HAP. Cure rates were 41% in the telavancin arm and 40% in the vancomycin arm. In patients with MRSA bacteremic HAP \((n=33)\), cure rates were 42% for the telavancin arm and 33% for the vancomycin arm. However, the study numbers were small and the results must be interpreted with caution.

Safety analysis of the ATTAIN trials was reported. Rates of adverse events were similar across both groups. However, severe adverse effects were higher among the telavancin arm as compared to the vancomycin arm \((21\% vs 16\%)\). The rates of treatment emergent adverse effects leading to study discontinuation were also higher in the telavancin arm as compared to the vancomycin arm \((8\% vs 5\%)\). Clinically significant renal function decline was also seen at a higher rate among the telavancin arm as compared to the vancomycin arm \((16\% vs 10\%)\). On the basis of these data,
patients receiving telavancin should be monitored closely with particular attention to renal function.

Complicated skin and skin structure infections

To understand the potential role of telavancin in treating SSIs, we reviewed the data on its use in treating cSSSIs. The telavancin vs standard therapy for cSSSIs caused by Gram-positive organisms (FAST) trials were two clinical trials comparing telavancin to standard care (vancomycin or anti-staphylococcal penicillin). In the first trial, the clinically evaluable population was 141. Cure was achieved in 79% of the telavancin arm vs 80% of the standard care arm. Among those study participants who were culture-positive for MRSA at baseline (n=48), 82% of patients in the telavancin arm achieved cure vs 69% in the standard care arm. Adverse events that could have possibly been related to therapy were seen in 32% in the telavancin arm as compared to 29% in the standard care arm. Vomiting, paresthesias, and dyspnea were seen at slightly higher rates in the telavancin arm. Severe adverse events were seen in fewer patients in the telavancin arm (3%) vs the standard care arm (7%).

The second trial by the FAST study group produced similar results as the first. While patients with creatinine clearance less than 50 mL/min were excluded from the first trial, the second trial included these individuals. Telavancin was renally dosed in this trial. The total number of clinically evaluable participants followed up to the test of cure visit was 154. Ninety-six percent of those in the telavancin arm achieved cure, which was comparable to 94% in the standard care arm (vancomycin or anti-staphylococcal penicillin). Rates of adverse events in both study arms were similar, 56% for telavancin and 57% for standard care. Rates of severe adverse events were also similar amongst both groups; 6% for the telavancin group and 4% for the standard care group.

The Assessment of Telavancin in Skin and Skin Structure Infections (ATLAS I and ATLAS II) trials were Phase III trials that also looked at the role of telavancin in treating cSSSIs. In these trials, telavancin at a dose of 10 mg/kg every 24 hours was compared to vancomycin 1 g every 12 hours. Pooling both studies, 579 participants had MRSA infections. Within this group, 91% of participants in the telavancin arm achieved cure compared to 84% in the vancomycin arm. The ATLAS trials formed the basis for FDA approval of telavancin for cSSSIs. A subanalysis of patients in the ATLAS trials focused on SSIs was also performed. Telavancin was compared to vancomycin. There were no significant differences between groups due to the small sample sizes. An analysis combining the ATLAS clinical trials showed that telavancin has a decreased efficacy among patients with moderate to severe renal function. Among those with creatinine clearance below 50 mL/min, cure rates were 67.4% in the telavancin arm as compared to 82.7% in the vancomycin arm. The reason for this finding is unclear. However, a study utilizing serum from renal disease patients following a dose of telavancin showed that in vitro activity of telavancin was maintained against a strain of S. aureus.

In the ATLAS trials, adverse events were reported for 79% of the telavancin arm vs 72% for the vancomycin arm. The most common side effects in the telavancin arm were taste disturbance, nausea/vomiting, and foamy urine. Serious adverse events were reported in 7% of the telavancin arm as compared to 5% of the vancomycin arm. The serious adverse events in the telavancin arm were primarily renal, respiratory, and cardiac events.

An important subset of soft tissue infections are complicated by prosthetic material. There is a lack of clinical trials evaluating the role of telavancin in treating staphylococcal infections producing biofilm. Biofilm production is known to complicate treatment of prosthetic device infections. The role of telavancin in treating infections complicated by prosthetic devices has been evaluated in vitro. Biofilm producing strains of staphylococci and enterococci were tested against telavancin and vancomycin. Comparing concentrations of 0–16 µg/mL, telavancin was more active against bacteria embedded in biofilms and inhibited new biofilm formation. At least two other in vitro studies have also shown that telavancin has greater activity against biofilm producing strains of Staphylococcus species. There have also been a few case reports showing successful treatment of infections complicated by prosthetic material.

Central line-associated bloodstream infections

CLABSI are frequently caused by Gram-positive bacteria. Telavancin, with its enhanced bactericidal activity against Gram-positive bacteria, could potentially play a role in treating these infections. The ASSURE (telavancin for treatment of uncomplicated bacteremia) trial was a Phase II clinical trial that compared telavancin and standard care (vancomycin or anti-staphylococcal penicillin) for the treatment of uncomplicated S. aureus bacteremia. Intravenous catheters were the most common cause of S. aureus bacteremia in this study. Fifty percent of patients had infections.
with MRSA. The clinically evaluable group within this study consisted of those who received study drugs for at least 12 days. There were eight patients in the telavancin arm and nine patients in the standard care arm among the clinically evaluable study participants. Cure rates were comparable across both groups, suggesting a potential role for telavancin in treating these infections. Given the small numbers in this Phase II trial, additional studies are needed before making any definitive conclusions. The small sample size of the ASSURE trial also means that safety data from this study may not be accurate. In this study, 90% of the people in the telavancin arm had at least one adverse event compared to 72% in the standard care arm. The most common adverse events were fever, headache, and rash.

There have been case reports showing successful use of telavancin in the treatment of MRSA bacteremia cases. One case report outlined the successful use of telavancin to treat a patient with persistent MRSA bacteremia in the setting of endocarditis. In this case, the patient had remained bacteremic for 10 days despite therapeutic vancomycin levels. After switching to telavancin 10 mg/kg, blood cultures became negative. Follow-up cultures 6 months after completion of therapy were also negative. Another case report outlined a successful treatment of VISA pacemaker lead infective endocarditis with combination of lead removal and telavancin. Joson et al have also published a case of successful treatment of mitral valve endocarditis with telavancin.

A study on the use of telavancin in treating bloodstream infections was presented at the 2014 Infectious Diseases Society of America meeting. In this study, 78 cancer patients with Gram-positive bloodstream infections received either vancomycin or telavancin. The bacterial isolates found were S. aureus (51%), followed by alpha-hemolytic streptococci (23%), Enterococcus (15%), coagulase-negative Staphylococcus (8%), and beta-hemolytic streptococci (3%). Fifty-one percent of participants were neutropenic at onset of therapy. There was a trend toward better clinical response in the telavancin arm compared to the vancomycin arm (83.3% vs 63.2%; P=0.051), but this did not achieve statistical significance. There have been review papers outlining existing data on the use of telavancin to treat bloodstream infections. Additional studies are needed to fully determine the role telavancin could play in Gram-positive endocarditis.

Catheter-associated urinary tract infections
Telavancin is primarily excreted by the kidneys. However, to our knowledge, there have not been any studies evaluating the role of telavancin in treating urinary tract infections. There is a need to look at the utility of this antibiotic for treating resistant Gram-positive causes of lower and upper urinary tract infections such as vancomycin-resistant E. faecium.

Safety and tolerability
A pooled analysis of five randomized controlled trials was performed which compared rates of mortality between telavancin and vancomycin groups. Data for this analysis were available for 3,565 patients. The rates of mortality were similar between telavancin and vancomycin groups; 8.9% vs 8.3%, OR=1.08 (95% CI, 0.84–1.38). However, among those with kidney dysfunction, data from a clinical trial of patients with HAP showed lower 28-day survival rates with telavancin as compared to vancomycin. Among patients with moderate to severe kidney dysfunction (creatinine clearance <50 mL/min), 28-day survival rates for telavancin (59%) were lower than vancomycin (70%). When analysis was further restricted to patients with very severe kidney disease (creatinine clearance <30 mL/min), 28-day survival was again lower in the telavancin arm (47%) vs the vancomycin arm (62%).

Telavancin has also been associated with higher rates of acute kidney injury. Pooled analysis of six randomized controlled trials (3,312 total patients) showed a 10% rate of kidney injury in the telavancin group compared to the vancomycin group at 5%, OR=2.22 (95% CI, 1.38–3.57). To our knowledge, telavancin did not cause end-stage renal disease in any of the study participants. Patients with preexisting kidney disease need to be monitored very closely if they are placed on telavancin. Besides acute kidney injury, other reported adverse events among those receiving telavancin included taste disturbance (31.6%), nausea (17.1%), headache (13.2%), constipation (9.3%), insomnia (7.7%), anemia (6.3%), and corrected QT interval prolongation (3.8%).

Telavancin has not been studied in pregnant women. However, in animal models, telavancin was associated with birth defects. Hence it should not be used in pregnant women.

Cost
An important factor that influences the use of an antibiotic is cost. Pharmacoeconomic analysis which compared the cost of telavancin against vancomycin for treatment of cSSSIs was performed. Data from the ATLAS Phase III clinical trial was utilized. This analysis was restricted to study participants who had been hospitalized. Variables in this analysis included infection-related length of hospital stay, infection-related cost, cost of vancomycin monitoring, and antibiotic acquisition prices. The sensitivity of their analysis was tested by incrementally increasing the cost per dose of telavancin up to 15 times the cost per dose of
vancomycin. The analysis found no significant difference in infection-related length of stay between telavancin and vancomycin.

There was also no significant difference in infection-related cost.

**Conclusion**

A summary of the cure rates of telavancin for treating infections is provided in Table 1. Data from clinical trials show that telavancin may be of particular use in the treatment of cSSSIs and HAP. There is a need for more clinical data on its use in treating bloodstream and urinary tract infections. In choosing an antibiotic for patients, clinicians would need to factor in drug efficacy, side effects, convenience, and cost. Telavancin has enhanced bactericidal activity against a range of drug-resistant Gram-positive organisms. It is also dosed once a day. However, acute kidney injury was noted in higher rates among those receiving telavancin as compared to vancomycin. Telavancin does not require therapeutic drug level monitoring as vancomycin does and may have a comparable overall cost to vancomycin.38 Additional clinical studies are needed to determine the role of telavancin in the treatment of CLABSI and CAUTI.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


---

**Table 1** Cure rates of telavancin for treating infections

<table>
<thead>
<tr>
<th>Clinical syndrome (sample size)</th>
<th>Telavancin (cure rate %)</th>
<th>Vancomycin or anti-staphylococcal penicillin (cure rate %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAP&lt;sup&gt;a&lt;/sup&gt; (n=654)</td>
<td>82</td>
<td>81</td>
</tr>
<tr>
<td>cSSSI (n=141)</td>
<td>79</td>
<td>80</td>
</tr>
<tr>
<td>cSSSI secondary to MRSA&lt;sup&gt;b&lt;/sup&gt; (n=579)</td>
<td>91</td>
<td>84</td>
</tr>
<tr>
<td>Bloodstream infection&lt;sup&gt;c&lt;/sup&gt; (n=17)</td>
<td>88</td>
<td>89</td>
</tr>
<tr>
<td>Urinary tract infections</td>
<td>No data</td>
<td>No data</td>
</tr>
</tbody>
</table>

Notes: ATTAiN trials<sup>a</sup>; FAST trials<sup>b</sup>; ATLAS trials<sup>c</sup>; ASSURe trials.<sup>d</sup>

Abbreviations: HAP, hospital-associated pneumonia; cSSSI, complicated skin and skin structure infection; MRSA, methicillin-resistant *Staphylococcus aureus.*


